| Product Unit Size | Cost | Quantity | Stock |
|---|
Exemestane is a third generation aromatase inhibitor that prevents estrogen synthesis and is clinically used to treat ER+ breast cancer. Exemestane exhibits anticancer chemotherapeutic activity, inhibiting proliferation and inducing cell cycle arrest, apoptosis, and autophagy in breast cancer cells.
| Cas No. | 107868-30-4 |
|---|---|
| Purity | ≥97% |
| Formula | C20H24O2 |
| Formula Wt. | 296.40 |
| Chemical Name | 6-Methyleneandrosta-1,4-diene-3,17-dione |
| IUPAC Name | (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15, 16-octahydrocyclopenta[a]phenanthrene-3,17-dione |
| Synonym | Aromasin, FCE-24304 |
| Melting Point | 188-191°C |
| Solubility | Soluble in methanol, ethanol (15 mg/mL), DMSO (54mg/mL) or dimethylformamide. Insoluble in water. |
| Appearance | Yellowish to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Amaral C, Borges M, Melo S, et al. Apoptosis and autophagy in breast cancer cells following exemestane treatment. PLoS One. 2012;7(8):e42398. PMID: 22912703.
Hong Y, Rashid R, Chen S. Binding features of steroidal and nonsteroidal inhibitors. Steroids. 2011 Jul;76(8):802-6. PMID: 21420422.
Bertelli G, Hall E, Ireland E, et al. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. Ann Oncol. 2010 Mar;21(3):498-505. PMID: 19717534.